Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage.
Reinhard AngermannTeresa RaucheggerYvonne NowosielskiMarina CasazzaAngelika BilgeriHanno UlmerClaus ZehetnerPublished in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2019)
We found a high long-term LTFU rate for patients with DR, despite treatment under universal health coverage. Considering the risk of disease progression, particularly in patients with chronic DR, strategies for better compliance and adherence to therapy should be considered for optimized patient care.
Keyphrases
- diabetic retinopathy
- vascular endothelial growth factor
- healthcare
- public health
- age related macular degeneration
- mental health
- health information
- type diabetes
- endothelial cells
- stem cells
- risk assessment
- glycemic control
- affordable care act
- editorial comment
- adipose tissue
- health promotion
- replacement therapy
- social media
- newly diagnosed
- cell therapy
- climate change